Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Rule

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximabBertrand Coiffier, Weimin Li, Erin D Henitz, et al.
Lancet (London, England)|October 6, 2025
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trialDavid J Lewis, Mats Jerkeman, Lexy Sorrell, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaMichael L Wang, Simon Rule, Peter Martin, et al.
Leukemia|August 13, 2020
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST studyCarlo Visco, Alice Di Rocco, Andrea Evangelista, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood Advances|August 10, 2022
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphomaFindlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximabBertrand Coiffier, Weimin Li, Erin D Henitz, et al.
Lancet (London, England)|October 6, 2025
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trialDavid J Lewis, Mats Jerkeman, Lexy Sorrell, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaMichael L Wang, Simon Rule, Peter Martin, et al.
Leukemia|August 13, 2020
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST studyCarlo Visco, Alice Di Rocco, Andrea Evangelista, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood Advances|August 10, 2022
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphomaFindlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
Pageof 8